S-217622, a 3CL Protease Inhibitor and Clinical Candidate for SARS-CoV-2.
Joel D A TyndallPublished in: Journal of medicinal chemistry (2022)
The coronavirus disease (COVID-19) pandemic has highlighted the ability of scientists to quickly react to the immense challenge presented to the world. The orally available 3CL protease inhibitor S-217622 is currently progressing through clinical trials and its discovery via structure-based drug design, screening and optimization by Shionogi and Hokkaido University is presented here.